XML 33 R20.htm IDEA: XBRL DOCUMENT v3.21.1
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

We do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. Potential dilutive securities result from outstanding stock options, restricted stock and “non-pre-funded” warrants. We did not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods presented:

 

   For the years ended December 31, 
   2020   2019 
Warrants   -    70,000 
Restricted stock   2,952,499    354,625 
Stock options   5,685,539    6,055,395 
Total   8,638,038    6,480,020 
SCHEDULE OF STOCK BASED COMPENSATION

The following table summarizes stock option-based option compensation for 2020 and 2019, which was allocated as follows:

 

   For the years ended December 31, 
   2020   2019 
Research and development  $3,126,000   $3,932,000 
General and administrative   2,727,000    3,406,000 
Stock option-based compensation expense included in operating expense   5,853,000    7,338,000 
           
Total stock option-based compensation expense   5,853,000    7,338,000 
Tax benefit   -    - 
Stock option-based compensation expense, net of tax  $5,853,000   $7,338,000 
Restricted Stock [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
SCHEDULE OF STOCK BASED COMPENSATION

The following table summarizes restricted stock-based compensation for 2020 and 2019, which was allocated as follows:

 

   For the years ended December 31, 
   2020   2019 
Research and development  $957,000   $454,000 
General and administrative   1,377,000    445,000 
Restricted stock-based compensation expense included in operating expense   2,334,000    899,000 
           
Total restricted stock-based compensation expense   2,334,000    899,000 
Tax benefit   -    - 
Restricted stock-based compensation expense, net of tax  $2,334,000   $899,000